Reminder starting in 2 hours: Under the Wire: Dr Phillip Altman regarding shocking new research indicating 1 in 35 COVID-boosted people may develop myocarditis
Join us on Sunday night, July 30th at 8 PM AEST - links in the post
The files from tonight’s show can be downloaded here for the next 30 days.
You can watch the program live at the following links:
And this will be available to view or listen to on Monday morning on Spotify
You can read Dr Altman’s Substack here -
Sunday, 30 July, 2023 at 8 PM AEST
This Sunday night, Dr Altman and I will be discussing the recent study out of Switzerland indicating that 1 person in 35 who has received the Moderna COVID booster has developed myocarditis leading to heart damage.
If we extrapolate that figure to those in Australia who have received COVID boosters, we would have an extremely large number of people whose hearts could literally be ticking timebombs. This might go some way towards explaining why so many fit and healthy athletes have been dying or having heart attacks on the field over the last couple of years.
We will also be covering several other issues including the lack of scientific rigour in vaccine testing and the over-emphasis on disease risk whilst downplaying the real risk of COVID injections.
Dr Altman’s experience in clinical trials gives him a unique perspective which goes a long way towards understanding how we’ve gotten to this point in only a bit over 3 years.
About Dr Altman
Dr Altman is a well-known Australian authority on clinical trials and regulatory affairs with more than 40 years of experience in designing, managing and reporting of clinical trials and in working with the Australian Therapeutic Goods Administration in gaining new drug approvals. He has worked in senior managerial positions for several multinational companies including Merrell-Dow, Hoechst, Roussel and GD Searle. He established Australia’s first contract research organisations (CROs), where he served as a Senior Industry Consultant for more than half of the pharmaceutical companies present in Australia. His career has seen him involved in more than one hundred clinical trials (Phase I through IV). He has been personally responsible for the market approval of numerous new drugs since joining the pharmaceutical industry in 1974.
Dr. Altman has a comprehensive working knowledge of the international pharmaceutical standards and guidelines involved in all aspects of drug development including drug chemistry, drug manufacture, quality control, animal and clinical safety and efficacy testing. This expertise allows Dr. Altman to critically evaluate any and all data prepared for use in the international registration of new drugs.
Informed Choice is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.
